Skip to main content
Erschienen in: CNS Drugs 7/2011

01.07.2011 | Therapy in Practice

Transdermal Rivastigmine

Management of Cutaneous Adverse Events and Review of the Literature

verfasst von: Jill Greenspoon, Nathan Herrmann, David N. Adam

Erschienen in: CNS Drugs | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease is a chronic neurodegenerative disorder resulting in part from the degeneration of cholinergic neurons in the brain. Rivastigmine, a cholinesterase inhibitor, is commonly used as a treatment for dementia due to its ability to moderate cholinergic neurotransmission; however, treatment with oral rivastigmine can lead to gastrointestinal adverse effects such as nausea and vomiting. Transdermal administration of rivastigmine can minimize these adverse effects by providing continuous delivery of the medication, while maintaining the effectiveness of the oral treatment. While the transdermal form of rivastigmine has been found to have fewer systemic adverse effects compared with the oral form, cutaneous reactions, such as contact dermatitis, can lead to discontinuation of the drug in its transdermal form. Lack of patient compliance with regard to applying the patch to the designated site, applying the patch for the correct length of time or rotating patch application sites increases the risk of cutaneous adverse reactions. This article outlines the diagnosis and management of irritant contact dermatitis and allergic contact dermatitis secondary to transdermal rivastigmine.
The large majority of reactions to transdermal patches are of an irritant type, which can be diagnosed clinically by the presence of a pruritic, erythematous, eczematous plaque strictly confined to the borders of the patch. In contrast, an allergic reaction can be differentiated by the presence of vesicles and/or oedema, erythema beyond the boundaries of the transdermal patch and lack of improvement of the lesion 48 hours after removal of the offending treatment. By encouraging the patient to follow a regular rotation schedule for the patch, and using lipid-based emollients for irritant dermatitis and pre- and post-treatment topical corticosteroids for allergic dermatitis, cutaneous reactions can often be alleviated and patients can continue with their medication regimen. Other simple changes to a patient’s treatment routine, including minimizing the use of harsh soaps, avoiding recently shaven or damaged areas of skin and carefully removing the patch after use, can help to further decrease the risk of dermatitis development.
Literatur
1.
Zurück zum Zitat Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease [letter]. Lancet 1976; 2: 1403PubMedCrossRef Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease [letter]. Lancet 1976; 2: 1403PubMedCrossRef
2.
Zurück zum Zitat Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer’s disease. CNS Drugs 1999; 12: 307–23CrossRef Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer’s disease. CNS Drugs 1999; 12: 307–23CrossRef
4.
Zurück zum Zitat Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65 Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65
5.
Zurück zum Zitat Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: S26–34 Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: S26–34
6.
Zurück zum Zitat Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; (127): 45-63 Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; (127): 45-63
7.
Zurück zum Zitat Winblad B, Grossberg B, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: 14–22CrossRef Winblad B, Grossberg B, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: 14–22CrossRef
8.
Zurück zum Zitat Lefèvre G, Sedek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther 2008; 83: 106–14PubMedCrossRef Lefèvre G, Sedek G, Jhee S, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther 2008; 83: 106–14PubMedCrossRef
9.
Zurück zum Zitat Zhai H, Maibach HI, editors. Dermatotoxicology. 6th ed. New York (NY): CRC Press LLC, 2004 Zhai H, Maibach HI, editors. Dermatotoxicology. 6th ed. New York (NY): CRC Press LLC, 2004
10.
Zurück zum Zitat Grossberg GT, Sadowsky S, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease. Int J Clin Pract 2010; 64: 534–6CrossRef Grossberg GT, Sadowsky S, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease. Int J Clin Pract 2010; 64: 534–6CrossRef
11.
Zurück zum Zitat Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22: 485–91PubMedCrossRef Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22: 485–91PubMedCrossRef
12.
Zurück zum Zitat Bernabei R, Martínez Lage P. Clinical benefits associated with a transdermal patch for dementia. Eur Neurol Rev 2008; 3: 10–3 Bernabei R, Martínez Lage P. Clinical benefits associated with a transdermal patch for dementia. Eur Neurol Rev 2008; 3: 10–3
14.
Zurück zum Zitat Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther 2009; 26: 920–35PubMedCrossRef Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther 2009; 26: 920–35PubMedCrossRef
15.
Zurück zum Zitat Widman TJ, Oostman H, Storrs FJ. Allergic contact dermatitis from medical adhesive bandages in patients who report having a reaction to medical bandages. Dermatitis 2008; 19: 32–7PubMed Widman TJ, Oostman H, Storrs FJ. Allergic contact dermatitis from medical adhesive bandages in patients who report having a reaction to medical bandages. Dermatitis 2008; 19: 32–7PubMed
16.
Zurück zum Zitat Sadowsky C, Dengiz A, Olin J, et al. Switching from done-zepil tablets to rivastigmine transdermal patch in Alzheimer’s disease. Am J Alz Dis Other Demen 2009; 24: 267–75CrossRef Sadowsky C, Dengiz A, Olin J, et al. Switching from done-zepil tablets to rivastigmine transdermal patch in Alzheimer’s disease. Am J Alz Dis Other Demen 2009; 24: 267–75CrossRef
17.
18.
Zurück zum Zitat Saary J, Qureshi R, Palda V, et al. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol 2005; 53: 845PubMedCrossRef Saary J, Qureshi R, Palda V, et al. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol 2005; 53: 845PubMedCrossRef
19.
Zurück zum Zitat Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010; 82: 249–55PubMed Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician 2010; 82: 249–55PubMed
20.
Zurück zum Zitat Zeller S, Warshaw E. Allergic contact dermatitis. Minn Med 2004; 87: 38–42PubMed Zeller S, Warshaw E. Allergic contact dermatitis. Minn Med 2004; 87: 38–42PubMed
21.
Zurück zum Zitat Loden M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis 1997; 36: 256–60PubMedCrossRef Loden M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis 1997; 36: 256–60PubMedCrossRef
22.
Zurück zum Zitat Loden M, Andersson AC. Effect of topically applied lipids on surfactant-irritated skin. Br J Dermatol 1996; 134: 215–20PubMedCrossRef Loden M, Andersson AC. Effect of topically applied lipids on surfactant-irritated skin. Br J Dermatol 1996; 134: 215–20PubMedCrossRef
23.
Zurück zum Zitat Queille-Roussel C, Duteil L, Padilla JM, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 2002; 27: 47–50CrossRef Queille-Roussel C, Duteil L, Padilla JM, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol 2002; 27: 47–50CrossRef
24.
Zurück zum Zitat Levin C, Zhai H, Bashir S, et al. Efficacy of corticosteroids in acute experimental irritant contact dermatitis. Skin Res Technol 2001; 7: 214–8PubMedCrossRef Levin C, Zhai H, Bashir S, et al. Efficacy of corticosteroids in acute experimental irritant contact dermatitis. Skin Res Technol 2001; 7: 214–8PubMedCrossRef
25.
Zurück zum Zitat Zhai H, Brachman F, Pelosi A, et al. A bioengineering study on the efficacy of a skin protectant lotion in preventing SLS-induced dermatitis. Skin Res Technol 2000; 6: 77–80PubMedCrossRef Zhai H, Brachman F, Pelosi A, et al. A bioengineering study on the efficacy of a skin protectant lotion in preventing SLS-induced dermatitis. Skin Res Technol 2000; 6: 77–80PubMedCrossRef
26.
Zurück zum Zitat Perrenoud D, Gallezot D, van Melle G. The efficacy of a protective cream in a real-world apprentice hairdresser environment. Contact Dermatitis 2001; 45: 134–8PubMedCrossRef Perrenoud D, Gallezot D, van Melle G. The efficacy of a protective cream in a real-world apprentice hairdresser environment. Contact Dermatitis 2001; 45: 134–8PubMedCrossRef
27.
Zurück zum Zitat Amkraut AA, Jordan WP, Taskovich I. Effect of coadministration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol 1996; 35: 27–31PubMedCrossRef Amkraut AA, Jordan WP, Taskovich I. Effect of coadministration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol 1996; 35: 27–31PubMedCrossRef
28.
29.
Zurück zum Zitat Berardesca E, Barbareschi M, Veraldi S, et al. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. Contact Dermatitis 2001; 45: 280–5PubMedCrossRef Berardesca E, Barbareschi M, Veraldi S, et al. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. Contact Dermatitis 2001; 45: 280–5PubMedCrossRef
30.
Zurück zum Zitat Berman B, France DS, Martinelli GP, et al. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids. J Invest Dermatol 1983; 80: 168–71PubMedCrossRef Berman B, France DS, Martinelli GP, et al. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids. J Invest Dermatol 1983; 80: 168–71PubMedCrossRef
31.
Zurück zum Zitat Toews GB, Bergstreser PR, Streilein JW. Epidermal Langerhans cell density determines whether contact hyper-sensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 1980; 124: 445–53PubMed Toews GB, Bergstreser PR, Streilein JW. Epidermal Langerhans cell density determines whether contact hyper-sensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 1980; 124: 445–53PubMed
32.
Zurück zum Zitat Lefevre G, Sedek G, Huang HL, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007; 47: 471–8PubMedCrossRef Lefevre G, Sedek G, Huang HL, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007; 47: 471–8PubMedCrossRef
33.
Zurück zum Zitat Arnold LE, Lindsay RL, Lopez FA, et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120: 1100–6PubMedCrossRef Arnold LE, Lindsay RL, Lopez FA, et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120: 1100–6PubMedCrossRef
Metadaten
Titel
Transdermal Rivastigmine
Management of Cutaneous Adverse Events and Review of the Literature
verfasst von
Jill Greenspoon
Nathan Herrmann
David N. Adam
Publikationsdatum
01.07.2011
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11592230-000000000-00000

Weitere Artikel der Ausgabe 7/2011

CNS Drugs 7/2011 Zur Ausgabe

Adis Drug Profile

Vilazodone

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.